Furthermore, it has been demonstrated that blockade of TGFβ-SMAD3 signaling regulates glucose tolerance and energy homeostasis, suggesting that modulating TGF-β activity may be an effective treatment strategy for obesity and diabetes [212]. Here, TGFB1 is linked to obesity due to melanocortin 4 receptor deficiency.